Cargando…

Iloprost in COVID-19: The Rationale of Therapeutic Benefit

Detalles Bibliográficos
Autores principales:	Faggioli, Paola Maria, Mumoli, Nicola, Mazzone, Antonino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102696/ https://www.ncbi.nlm.nih.gov/pubmed/33969013 http://dx.doi.org/10.3389/fcvm.2021.649499

Ejemplares similares

Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
por: Restelli, Umberto, et al.
Publicado: (2015)

Monocytes could be a bridge from inflammation to thrombosis on COVID-19 injury: A case report
por: Mazzone, Antonino, et al.
Publicado: (2020)

Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
por: Zizzo, Gaetano, et al.
Publicado: (2022)

Reorganizing Italian Internal Medicine wards for COVID 19
por: Mazzone, Antonino, et al.
Publicado: (2020)

Man with fever, cough, and weakness
por: Mumoli, Nicola, et al.
Publicado: (2020)

COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma
por: Colombo, Daniele, et al.
Publicado: (2022)

Clinical immunity in discharged medical patients with COVID-19
por: Mumoli, Nicola, et al.
Publicado: (2020)

Cardiac injury as prognostic value in COVID-19: more remains to be clarified
por: Mumoli, Nicola, et al.
Publicado: (2020)

Telemedicine: Benefits for Cardiovascular Patients in the COVID-19 Era
por: Ghilencea, Liviu-Nicolae, et al.
Publicado: (2022)

Iloprost as an acute kidney injury-triggering agent in severely atherosclerotic patients
por: Uyar, Mehtap Erkmen, et al.
Publicado: (2016)

Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience
por: Castelnovo, Laura, et al.
Publicado: (2021)

The rationale for the treatment of long-Covid symptoms – A cardiologist's view
por: Schieffer, Elisabeth, et al.
Publicado: (2022)

Iloprost for COVID-19-related vasculopathy
por: Moezinia, Carine J, et al.
Publicado: (2020)

Corrigendum: The rationale for the treatment of long-COVID esymptoms—a cardiologist's view
por: Schieffer, Elisabeth, et al.
Publicado: (2023)

The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels
por: Suna, Aydin, et al.
Publicado: (2017)

Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review
por: Laria, Antonella, et al.
Publicado: (2022)

The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis
por: Stojanovic, Dijana, et al.
Publicado: (2022)

Transient perivascular inflammation of the carotid artery (TIPIC) syndrome in a patient with COVID-19
por: Mumoli, Nicola, et al.
Publicado: (2021)

The Meaning of D-Dimer value in Covid-19
por: Conte, Giulia, et al.
Publicado: (2021)

Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
por: Graziani, Francesca, et al.
Publicado: (2021)

The Palma Echo Platform: Rationale and Design of an Echocardiography Core Lab
por: López, Luis, et al.
Publicado: (2022)

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
por: Kostapanos, Michael S., et al.
Publicado: (2019)

Post-COVID or long-COVID: Two different conditions or the same?
por: Mumoli, Nicola, et al.
Publicado: (2021)

Iloprost for the treatment of frostbite: a scoping review
por: Gauthier, Josianne, et al.
Publicado: (2023)

Iloprost in Acute Post-kidney Transplant Atheroembolism: A Case Report of Two Successful Treatments
por: Corradetti, Valeria, et al.
Publicado: (2020)

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
por: Kotecha, Dipak, et al.
Publicado: (2017)

Cardio-Oncology Rehabilitation and Telehealth: Rationale for Future Integration in Supportive Care of Cancer Survivors
por: Batalik, Ladislav, et al.
Publicado: (2022)

The Aswan Rheumatic heart disease reGIstry: rationale and preliminary results of the ARGI database
por: Kotit, Susy, et al.
Publicado: (2023)

Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review
por: Jamart, Céline, et al.
Publicado: (2022)

Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol
por: Meijers, Thomas A, et al.
Publicado: (2020)

Comorbidity of Type 2 Diabetes Mellitus and Depression: Clinical Evidence and Rationale for the Exacerbation of Cardiovascular Disease
por: Zhu, Mengmeng, et al.
Publicado: (2022)

Schnitzler syndrome, a rare autoinflammatory disease. Complete response to IL-1 blockade
por: Faggioli, Paola, et al.
Publicado: (2017)

Superior mesenteric artery-related outcomes in fenestrated/branched endografting for complex aortic aneurysms
por: Gallitto, E., et al.
Publicado: (2023)

Vascular Inflammation as a Therapeutic Target in COVID-19 “Long Haulers”: HIITing the Spot?
por: Christensen, Regitse Højgaard, et al.
Publicado: (2021)

Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study
por: Cheng, Yangyang, et al.
Publicado: (2019)

Antibiotic-Eluting Envelopes for the Prevention of Cardiac Implantable Electronic Device Infections: Rationale, Efficacy, and Cost-Effectiveness
por: Traykov, Vassil, et al.
Publicado: (2022)

ECG-Based Techniques to Optimize Peripherally Inserted Central Catheters: Rationale for Tip Positioning and Practical Use
por: Gullo, Giuseppe, et al.
Publicado: (2022)

Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence
por: Nopp, Stephan, et al.
Publicado: (2022)

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR)
por: Di Santo, Pietro, et al.
Publicado: (2023)

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study
por: Cacciottolo, Paul J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fic8en3tgp4p8va63rqtvpdp8j